OptiNose — Investor Presentation (April 2023)
17 slides from OptiNose's investor presentation, Apr 17, 2023
Slide 1: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n A p r i l 1 7 , 2 0 2 3 Exhibit 99.1
Slide 2: Forward-Looking Statements
2 Forward‐Looking Statements This presentation and our accompanying remarks contain “forward‐looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward‐looking statements for this
Slide 3: Key Takeaways
3 Key Takeaways Chronic sinusitis is a 10‐fold market opportunity for XHANCE We refocused our strategy to prioritize the potential launch of XHANCE as the first‐ever FDA approved drug treatment for CS Submitted sNDA in February ‐ acceptance decision by FDA anticipated by the start of May 2023 Potent
Slide 4: XHANCE as First FDA-approved Drug Treatment for Chronic Sinusitis Creates New Growth Opportunities
4 Successful Development of XHANCE as the First FDA‐approved Drug Treatment for Chronic Sinusitis Creates Multiple New Opportunities for Growth Up to ~1 Million patients with nasal polyps (NP) are treated by specialty physicians in our current sales deployment $1B TAM $3B TAM Up to ~10 Million patie
Slide 5: ReOpen Program
optinose_ ———— ReOpen Program
Slide 6: Combined Symptom Score (Co-Primary Endpoint)
6 Combined Symptom Score (Co‐Primary Endpoint) Improvement in combined symptoms with XHANCE; Consistent with NAVIGATE I and II 1 ‐0.81 ‐1.54* ‐1.74‡ ‐2.0 ‐1.8 ‐1.6 ‐1.4 ‐1.2 ‐1.0 ‐0.8 ‐0.6 ‐0.4 ‐0.2 0.0 CS S Po in t R ed uc tio n LS Mean Change in CSS from Baseline to Week 4 EDS‐placebo BID OPN‐375
Slide 7: Average of Percentages of Opacified Volume (Ethmoid and Maxillary)
7 Average of Percentages of Opacified Volume (Ethmoid and Maxillary) Objective Evidence of Effect in Sinus Cavities by CT Scan; Co‐Primary Endpoint 1.19 ‐7.00‡ ‐5.14♰ ‐8 ‐7 ‐6 ‐5 ‐4 ‐3 ‐2 ‐1 0 1 2 Pe rc en t R ed uc tio n LS Mean Change in APOV of the Ethmoid and Maxillary Sinuses from Baseline to W
Slide 8: CS Supplemental NDA - Anticipated Next Steps
8 CS Supplemental NDA ‐ Anticipated Next Steps As planned, we submitted our supplemental new drug application (sNDA) in pursuit of a new indication in February 2023 ‐ Submission acceptance decision by FDA anticipated by the start of May 2023 ‐ Assuming acceptance and a standard review period FDA’s
Slide 9: FY 2022 Performance
FY 2022 Performance
Slide 10: XHANCE New and Total Prescriptions
10 XHANCE New and Total Prescriptions XHANCE New Prescriptions were flat and Total Prescriptions for Full Year 2022 Estimated based on monthly prescription data from third parties and XHANCE preferred pharmacy network. The Market on this slide is defined as the sum of all intranasal steroid prescrip
Slide 11: FY 2022 XHANCE Net Revenue and Net Revenue per Prescription
11 FY 2022 XHANCE Net Revenue and Net Revenue per Prescription XHANCE Net Revenue increased 4% for Full Year 2022 and Average Net Revenue per TRx increased from $219 to $224 for Full Year 2022 $73.7 $76.3 FY 2021 FY 2022 Net Revenue +4% ($M) $219 $224 FY 2021 FY 2022 +2% Average Net Revenue per TRx
Slide 12: 2023 Outlook
optinose_ ———— 2023 Outlook
Slide 13: Full Year and Q1 2023 Financial Guidance
13 Full Year and Q1 2023 Financial Guidance Operating Expense (GAAP) ‒ Actions taken to reduce FY 2023 operating expenses by ~$30 million compared to FY 2022 actual of $123 million ‒ Expected to be between $90 to $95 million; approximately $8 million of which represents stock‐based compensation
Slide 14: Closing Remarks
optinose_ ———— Closing Remarks
Slide 15: Key Takeaways
15 Key Takeaways Chronic sinusitis is a 10‐fold market opportunity for XHANCE We refocused our strategy to prioritize the potential launch of XHANCE as the first‐ever FDA approved drug treatment for CS Submitted sNDA in February ‐ acceptance decision by FDA anticipated by the start of May 2023 Poten
Slide 16: Investor Relations - Optinose Investor Contact
16 Investor Relations – NASDAQ: OPTN Optinose Investor Contact Jonathan Neely, VP, Investor Relations and Business Development 267‐521‐0531 [email protected] As of December 31, 2022: – $94.2 million in cash – Debt: $130 million – 111.5 million common shares o/s – 43.6 million options, warrants
Slide 17: Building a Leading ENT / Allergy Specialty Company
Building a Leading ENT / Allergy Specialty Company Co r p o r a t e P r e s e n t a t i o n A p r i l 1 7 , 2 0 2 3